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Biosynthesis of polyketides can depend on interactions between the acyl carrier proteins (ACPs) which hold
the growing chains and their enzymatic partners. In this issue of Chemistry & Biology, Bruegger and
colleagues demonstrate that mechanism-based probes tethered to the ACPs of fungal nonreducing polyke-
tide synthases can provide insights into these contacts.Many people owe their good health to the
polyketide natural products and their syn-
thetic derivatives, as these compounds
are used clinically to treat a wide range
of both acute and degenerative diseases,
from bacterial infections to organ rejec-
tion and cancer (Hertweck, 2009). This
therapeutic value motivates interest in
finding further analogs of polyketides
with useful biological properties. One
approach that has attracted considerable
attention is to genetically engineer the
enzyme systems responsible for their
biosynthesis—the polyketide synthases
(PKSs) (Weissman and Leadlay, 2005).
Although united by a common chemistry
of chain building, the PKSs display a
bewildering variety of architectures
(Figure 1), from gigantic polypeptides
comprising multiple catalytic domains
(type I) to dissociable complexes of
discrete enzymes (type II) and individual,
multifunctional catalysts (type III). Adding
to this complexity, the type I systems are
further divided into the modular class, in
which there is a set of domains (a module)
for catalyzing each round of chain exten-
sion and processing reactions, and the
iterative PKS, in which one set of activities
is used repeatedly. In fact, fungal iterative
PKS come in at least three flavors—
highly-, partially-, or nonreducing (NR)-
PKS—depending on the level of reductive
tailoring that occurs during each cycle of
chain assembly (Cox, 2007).
All known type I and type II systems
employ a solid-phase synthetic strategy,
in that the growing chains are tethered to
small, noncatalytic proteins called acyl
carrier proteins (ACPs) via the thiol termi-
nus of a phosphopantetheine prosthetic
group (Crosby and Crump, 2012). This
biosynthetic feature offers several ad-
vantages, including maintaining thechains in a chemically activated state
and permitting the intermediates to be
channeled between the various active
sites. In addition, the substrate for any
particular reaction is not simply the acyl
chain itself, but the entire acyl-ACP
unit, potentially introducing an additional
level of molecular recognition into the
catalysis. Nonetheless, it is not at all
obvious that each enzymatic activity
must form a specific protein-protein
complex with the ACP to affect its chem-
istry, because many of the interactions in
both type I and type II systems between
ACPs and their partners are effectively
intramolecular (Weissman and Mu¨ller,
2008). What is clear, however, is that
understanding if and how ACP-partner
interactions occur, and how they are
regulated, is fundamental to successful
efforts to reconfigure PKS using genetic
approaches.
The method pioneered by the Burkart
group to analyze communication between
acyl-ACPs and the ketosynthases (KS)
responsible for chain extension is to
modify the ACPs with a mechanism-
based inhibitor of the KS (Meier and Bur-
kart, 2009). In this way, the chain can be
positioned appropriately within the KS
active site, enabling an efficient reaction
with its nucleophilic cysteine. The result
is the covalent cross-linking of the two do-
mains, the extent of which can be quanti-
fied by gel-shift assay. From previous
studies with type I modular and type II
PKS using complementary biophysical
methods (e.g., Worthington et al., 2006),
it has been demonstrated that the ACP
and KS domains do form a protein com-
plex during the catalysis. As cross-linking
efficiency closely correlates with the
measured strengths of these interactions,
it serves as a rapid means to determineChemistry & Biology 20, September 19, 2013 ªwhether a specific complex forms or
not. Furthermore, by varying the structure
of the ACP-tethered ‘‘warhead’’ and
measuring the effect on the cross-linking,
it is possible to simultaneously interrogate
KS substrate specificity.
In nonreducing PKS, the KS domain
not only synthesizes the poly-b-ketone
chain, but also contributes to chain-
length control (Crawford and Townsend,
2010). It may also act as a gatekeeper
of product structure, through its speci-
ficity for the starter unit; this building
block is selected by the upstream
‘‘starter unit-ACP transacylase’’ (SAT)
domain (Figure 1), transferred onto the
ACP, and then transacylated onto the
KS. Thus, it is of significant interest to un-
derstand how the KS interacts with the
various acyl-ACP species generated dur-
ing the synthetic cycles, because this
may permit the swapping of KS domains
between different systems in order to
vary multiple structural features of the
final product. In this issue of Chemistry
& Biology, Bruegger, et al. (2013) chose
as model NR-PKS systems Pks4, which
generates the polyketide core of the
anti-cancer bikaverin, and PksA, which
is involved in the biosynthesis of the
notorious peanut carcinogen aflatoxin.
Interactions between the KS and ACP
domains in these systems were probed
with three distinct cross-linkers, two of
which mimic the respective acetyl and
hexanoyl starter units of the two polyke-
tides, and a third, which resembles a
chain-extension intermediate, although
it is entirely lacking the characteristic
b-ketone groups. Cross-linker modified
forms of both ACPs were then incubated
with the KS domains of the two systems,
and the extent of cross-linking was
evaluated.2013 Elsevier Ltd All rights reserved 1089
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Figure 1. Schematic of the Three Types of PKS
(A) Type III PKSs consist of a single multifunctional active site, which, in cooperation with CoA-bound sub-
strates, performs all the steps necessary to assemble a polyketone chain of defined length.
(B) Type II PKSs comprise discrete catalytic functions which associate into a productive complex. The
‘‘minimal PKS’’ includes the KSa, KSb, and ACP domains, which iterate through a defined number of
chain-extension cycles to construct a polyketone chain.
(C) Type I PKSs consist of multifunctional polypeptides. In themodular subtype, each subunit contains one
or moremodules that incorporate a set of individually folded catalytic domains. Eachmodule typically acts
once to accomplish a round of chain extension and associated reductive processing reactions. In the iter-
ative class (exemplified here by a nonreducing [NR]-PKS), the domains of a single polypeptide act repeat-
edly to construct a chain of precise length and functionality.
Abbreviations: KS, ketosynthase; ACP, acyl carrier protein; AT, acyl transferase; KR, ketoreductase; SAT,
starter unit-ACP transacylase; MAT, malonyl-CoA-ACP transacylase; PT, product template; TE-CLC,
thioesterase-Claisen cyclase.
Chemistry & Biology
PreviewsFrom these experiments, the authors
were able to draw several important con-
clusions concerning ACP/KS interactions1090 Chemistry & Biology 20, September 19,in NR-PKS. First, the yield of cross-linked
species was highest for the cross-linker
that matched the substrate specificity of2013 ª2013 Elsevier Ltd All rights reservedthe KS domains. Thus, both the SAT
and the KS domains contribute to the
fidelity of chain initiation in NR-PKS.
Second, cross-linking was observed
only between the KS domains and the
ACPs derived from the two NR-PKS and
not with a selection of ACPs from type I
modular and type II PKS. This result
strongly supports the existence of a spe-
cific interface between the ACP and KS
domains. Furthermore, the fact that
cross-linking occurred with nearly equal
efficiency for all KS/ACP combinations
shows that the interface residues are
likely to be conserved between NR-PKS
systems. Indeed, in recent work by
several of the authors (Vagstad et al.,
2013), chain extension was reconstituted
with nearly equal efficiency with a single
NR-PKS KS and ACPs sourced from mul-
tiple systems, supporting the inherent
interchangeability of the domains. Thus,
it appears that the specific recognition
motifs for KSs and their ACP partners in
NR-PKSwill not be critical for the success
of KS swaps, because they appear to be
conserved.
Finally, using a combination of
homology modeling and computational
docking, the authors identified several
positively-charged residues near the KS
active site, which they proposed to
interact with similarly-conserved nega-
tively-charged amino acids on the ACP
surfaces. Despite the obvious caveats
associated with such docking studies in
the absence of high-resolution structures
of both partners, mutation of the identified
residues of both PksA and Pks4 KS had
measurable effects on the cross-linking
reactions with their cognate ACPs. Thus,
not only can the cross-linking approach
be used to demonstrate the existence of
a protein-protein complex, it also can
provide evidence for proposed interface
residues. Nonetheless, given that this
method remains only an indirect means
to probe interdomain contacts, indepen-
dent validation must come from more
direct approaches for visualizing inter-
faces, such as NMR and X-ray
crystallography.REFERENCES
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Contrary to the standard of eliminating antimicrobial hits that collapse bacterial proton motive force (PMF), in
this issue ofChemistry and Biology, Farha and colleagues describe the value of screens to identify molecules
that dissipate PMF, yet are nonbacteriolytic and selectively toxic.The urgent need to discover and develop
novel antimicrobial agents is underscored
by the rapid spread of bacterial patho-
gens exhibiting resistance to most clas-
ses of clinically used antibiotics. Yet, the
indispensable bacterial membrane that
houses several essential proteins and
the prokaryotic respiratory chain remain
underexploited for discovering new anti-
biotics (Hurdle et al., 2011). It is well
accepted that newly discovered antimi-
crobial chemotypes should be efficacious
against multi-drug resistant organisms,
while avoiding cytotoxicity or adverse
toxicity in animals, to warrant progression
as clinical candidates (O’Neill and Cho-
pra, 2004). In this regard, chemical
libraries of natural and synthetic origins
have been extensively screened by aca-
demic groups and pharmaceutical com-
panies to find new antibiotic chemotypes.
Such screens routinely identify hits with
potent antibacterial activity but often
result in the disturbance of the functional
integrity and associated bioenergetics of
the prokaryotic membrane (Payne et al.,
2007). These hits include molecules that
inhibit the bacterial respiratory chain,
lyse or induce curvature of the cyto-
plasmic membrane, or possess a mode
of action that is challenging to elucidate,
such as molecules that co-interact with
the membrane and peptidoglycan com-ponents or membrane embedded pro-
teins (Figure 1) (Hurdle et al., 2011;
Pogliano et al., 2012). Many of these hits
contain lipophilic moieties and also cause
damage to mammalian membranes or
display cytotoxicity, making them unde-
sirable for progression. Therefore, a near
consensus has emerged in the antibiotic
discovery field that such molecules are
nuisances that should be removed early
in the drug discovery process to avoid
downstream toxicity problems in mam-
mals (O’Neill and Chopra, 2004; Payne
et al., 2007). Hence counter-screening
assays have been exploited to eliminate
hits disrupting the functional properties
of the membrane. Although it is certainly
pertinent to eliminate molecules that are
cytotoxic and cause leakage of the pro-
karyotic cytosol, which could induce
septicemia, it is now apparent that not
all molecules targeting the functional
properties of the bacterial membrane are
undesirable or even lack a therapeutic in-
dex for safe use in humans (Hurdle et al.,
2011). Indeed, within the last decade, we
have seen the clinical development of
the drugs daptomycin and telavancin,
whose potency in part arise from mem-
brane interaction; the ongoing clinical
development of membrane-active agents
such as HT61 and XF73 for nasal decolo-
nization of methicillin-resistant Staphylo-coccus aureus; and the emergence of
the respiratory chain as a leading drug
target in Mycobacterium tuberculosis
(Hurdle et al., 2011; Koul et al., 2011). As
demonstrated with daptomycin, some
antimicrobial peptides and other mem-
brane-active molecules, selective killing
of bacteria can be achieved by exploiting
themajor differences in the lipid composi-
tions between prokaryotic and mamma-
lian membranes (Hurdle et al., 2011;
Verkleij et al., 1973). These examples
therefore challenge the traditional view
that themembrane is an unsuitable target.
Thus, in this issue of Chemistry & Biology,
the study by Farha et al. (2013) is valiant
and against the mainstream dogma, in
that it seeks to prioritize rather than
eliminate membrane-active hit molecules.
This may well prompt revisiting such mol-
ecules that have been discarded because
they affect the bacterial membrane
properties.
In their strategy, Farha et al. (2013) opti-
mized the standard assay that adopts the
membrane-potential sensitive dye 3,5-
dipropylthiacarbocyanine [DISC3(5)] to
screen for molecules that either dissipate
the electrical potential (Dc) or the proton
gradient (DpH) of the S. aureusmembrane
(Figure 1). Paradoxically, DiSC3(5) assays
have been exploited by others to remove
membrane-active molecules (Gentry2013 Elsevier Ltd All rights reserved 1091
